Skip to main content
. Author manuscript; available in PMC: 2023 Jun 22.
Published in final edited form as: Gynecol Oncol. 2023 Mar 8;171:141–150. doi: 10.1016/j.ygyno.2023.01.010

Table 2.

Adverse Events.

Adverse event Chemotherapy Backbone Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Hematologic
Leukopenia CDDP-Paclitaxel 42 24 76 71 10 0
Topotecan-Paclitaxel 28 26 49 79 35 0
Neutropenia CDDP-Paclitaxel 54 19 42 49 59 0
Topotecan-Paclitaxel 47 6 24 61 79 0
Anemia CDDP-Paclitaxel 17 47 103 50 6 0
Topotecan-Paclitaxel 12 50 104 44 7 0
Thrombocytopenia CDDP-Paclitaxel 130 65 18 8 2 0
Topotecan-Paclitaxel 110 82 11 7 7 0
Non-hematologic
Nausea CDDP-Paclitaxel 76 85 44 18 0 0
Topotecan-Paclitaxel 100 77 34 6 0 0
Vomiting CDDP-Paclitaxel 142 37 32 11 1 0
Topotecan-Paclitaxel 165 33 13 6 0 0
Gastrointestinal CDDP-Paclitaxel 51 80 61 29 1 1
Topotecan-Paclitaxel 70 63 63 19 1 1
Metabolic CDDP-Paclitaxel 118 44 29 31 1 0
Topotecan-Paclitaxel 141 38 25 12 1 0
Neurosensory CDDP-Paclitaxel 84 75 44 20 0 0
Topotecan-Paclitaxel 85 91 36 5 0 0
Allergy CDDP-Paclitaxel 178 18 19 8 0 0
Topotecan-Paclitaxel 203 9 2 3 0 0